Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: Results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy

Journal of Cardiovascular Medicine

Volumn 9, Issue 9, 2008, Pages 878-887

  Rapezzi, Claudio ^a   Biagini, Elena ^a   Bellis, Paolo ^b   Cafiero, Massimo ^c   Velussi, Mario ^d   Ceriello, Antonio ^e   Cooke, Robin M T ^a   Schweiger, Carlo ^f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Loreto Mare Hospital   (Italy)

^c MONALDI HOSPITAL   (Italy)

^d Nursing Home Pineta Karst   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f Hospital of Passirana of Rho   (Italy)

Author keywords

Cardiovascular prevention; Low density lipoprotein cholesterol; Risk factors; Statins; Us national cholesterol education program

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DECISION MAKING; DIABETES MELLITUS; DYSLIPIDEMIA; EVALUATION; FEMALE; HEALTH EDUCATION; HIGH RISK PATIENT; HISTORY; HUMAN; INTERVENTION STUDY; ITALY; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT; OUTPATIENT DEPARTMENT; PHYSICIAN; PILL; PRACTICE GUIDELINE; PREDICTION; PREDICTOR VARIABLE; PREVALENCE; PROPHYLAXIS; REGRESSION ANALYSIS; RISK; RISK ASSESSMENT; SEX; UNITED STATES; AMBULATORY CARE; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

AGED; AMBULATORY CARE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 55249089482     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282f56513     Document Type: Article

References (47)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18:1231-1248.
2. American Heart Association. Heart and stroke facts: 1996 statistical supplement. Dallas, TX; 1995.
3. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project. Contribution of trends in survival and coronary-eventrates to change in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353:1547-1557.
4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatmentofhigh blood cholesterol in adults (adulttreatment panel II). JAMA 1993; 269:3015-3023.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994; 344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in man with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995; 333:1301-1307.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335:1001 -1009.
8. Hebert PR, Gaziano JH, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality. JAMA 1997; 278:313-321.
9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in man and women with average cholesterol levels. AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349 -1357.
11. Pedersen TR, Olsson AG, Faergeman, Okiekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence ofmajor coronaryheart disease events in the Scandinavian Simvastatin Survival Study. Circulation 1998; 97:1453-1460.
12. Law MR, Wald NJ, Rudnicke AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-1431.
13. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al., Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267 -1278.
14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004; 363:685-696.
15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
16. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
17. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48:438 - 445.
18. Wood D, De Backer G, Faergeman D, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendation of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434-1503.
19. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatmentofhigh blood cholesterol in adults (adulttreatment panel III). JAMA 2001; 285:2486-2497.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
21. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low- density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459 -467.
22. Lai LL, Poblet M, Bello C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J 2000; 93:283-286.
23. Primatesta P, Poulter NR. Lipid concentrations and the use oflipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321 :1322 -1325.
24. Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al., 3T Study Investigators. A 52-week, multicentre, randomised, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther 2003; 25:119 -138.
25. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357:995-1001.
26. Nash IS, Mosca L, Blumenthal RS, Davidson MH, Smith SC, Pasternak RC. Contemporary awareness and understanding ofcholesterol as a risk factor. Results ofan American Heart Association national survey. Arch Intern Med 2003; 163:1597-1600.
27. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al., National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications ofrecent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-239.
28. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111 :499-510.
29. Wilson A, Pearson D, Hassey A. Barriers to developing the nurse practitioner role in primary care-the GP perspective. Fam Pract 2002; 19:641 -646.
30. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19:596-604.
31. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results ofthe National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005; 96:556 -563.
32. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004; 255:494-502.
33. Foley KA, Simpson RJ, Crouse JR III, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92:79 -81.
34. Fonarow GC, French WJ, Parson LS, Sun H, Malmgren JA. Use of lipid-lowering medication at discharge in patients with acute myocardial infarction. Data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103:38 -44.
35. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23:1177 -1189.
36. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ2001; 322:1463.
37. Wright DJ, Grayson AD, Jackson M, Dainty C. The reality of treating dyslipidemia in patients with coronary heart disease: a primary care survey. Int J Clin Pract 2003; 57:488-491.
38. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROSPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22:554-572.
39. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors ofcardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161 :1621-1628.
40. Foley KA, Massing MW, Simpson RJ, Alexander CM, Markson LE. Population implications of changes in lipid management in patients with coronary heart disease. Am J Cardiol 2004; 93:193-195.
41. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18:1569 -1582.
42. Schedlbauer A, Schroeder K, Fahey T, Peters T. Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews Art. No. CD004371.
43. Schedlbauer A, Schroeder K, Fahey T. How can adherence to lipid- lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract 2007; 24:380-387.
44. Friedewald WT, Levy RI, Fredrickson DS. Estimation ofthe concentration of low-density lipoprotein cholesterol in plasma, withoutuse of the preparative ultracentrifuge. Clin Chem 1972; 18:499 -502.
45. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
46. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174.
47. Colivicchi F, Uguccioni M, Ragonese M, Nardozi C, Angotti S, Principe F, et al. Cardiovascular risk factor control among diabetic patients attending community-based diabetic care clinics in Italy. Diabetes Res Clin Pract 2007; 75:176 -183.